 Stephen Waldo
Concepts (392)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 68 | 2023 | 445 | 18.090 |
Why?
| | Coronary Artery Disease | 42 | 2023 | 608 | 11.040 |
Why?
| | United States Department of Veterans Affairs | 27 | 2023 | 557 | 4.120 |
Why?
| | Peripheral Arterial Disease | 25 | 2020 | 380 | 3.790 |
Why?
| | Myocardial Infarction | 27 | 2023 | 930 | 3.660 |
Why?
| | Coronary Angiography | 30 | 2023 | 307 | 3.650 |
Why?
| | Endovascular Procedures | 18 | 2020 | 268 | 3.540 |
Why?
| | Femoral Artery | 13 | 2022 | 168 | 2.960 |
Why?
| | Veterans | 15 | 2023 | 1238 | 2.870 |
Why?
| | Treatment Outcome | 84 | 2023 | 9123 | 2.850 |
Why?
| | Vascular Calcification | 9 | 2022 | 107 | 2.550 |
Why?
| | Stents | 21 | 2019 | 476 | 2.510 |
Why?
| | ST Elevation Myocardial Infarction | 6 | 2022 | 51 | 2.320 |
Why?
| | Popliteal Artery | 11 | 2020 | 59 | 2.300 |
Why?
| | Registries | 28 | 2023 | 1763 | 2.240 |
Why?
| | Atherectomy | 11 | 2022 | 33 | 2.120 |
Why?
| | Acute Coronary Syndrome | 6 | 2022 | 254 | 2.020 |
Why?
| | Risk Factors | 65 | 2023 | 8642 | 2.010 |
Why?
| | Coronary Artery Bypass | 7 | 2023 | 196 | 1.970 |
Why?
| | Ischemia | 11 | 2020 | 363 | 1.940 |
Why?
| | Atherectomy, Coronary | 5 | 2022 | 11 | 1.850 |
Why?
| | Lower Extremity | 4 | 2018 | 337 | 1.760 |
Why?
| | Radial Artery | 7 | 2022 | 66 | 1.680 |
Why?
| | Angioplasty, Balloon, Coronary | 6 | 2017 | 146 | 1.650 |
Why?
| | Aged | 74 | 2023 | 19122 | 1.630 |
Why?
| | United States | 51 | 2023 | 12227 | 1.630 |
Why?
| | Veterans Health | 6 | 2020 | 165 | 1.630 |
Why?
| | Risk Assessment | 26 | 2022 | 2976 | 1.590 |
Why?
| | Platelet Aggregation Inhibitors | 7 | 2023 | 399 | 1.590 |
Why?
| | Time Factors | 45 | 2020 | 6141 | 1.570 |
Why?
| | Time-to-Treatment | 4 | 2019 | 147 | 1.550 |
Why?
| | Cardiovascular Agents | 7 | 2023 | 125 | 1.480 |
Why?
| | Biological Products | 2 | 2023 | 171 | 1.420 |
Why?
| | Non-ST Elevated Myocardial Infarction | 3 | 2020 | 16 | 1.410 |
Why?
| | Hospitals, Veterans | 3 | 2020 | 244 | 1.400 |
Why?
| | Humans | 143 | 2023 | 115049 | 1.390 |
Why?
| | Middle Aged | 70 | 2023 | 26830 | 1.390 |
Why?
| | Hospital Mortality | 12 | 2021 | 777 | 1.370 |
Why?
| | Coronary Restenosis | 4 | 2017 | 18 | 1.290 |
Why?
| | Angioplasty, Balloon | 9 | 2020 | 89 | 1.260 |
Why?
| | Male | 86 | 2023 | 55735 | 1.180 |
Why?
| | Myocardial Revascularization | 3 | 2019 | 67 | 1.170 |
Why?
| | Access to Information | 2 | 2019 | 49 | 1.130 |
Why?
| | Catheterization, Peripheral | 2 | 2019 | 102 | 1.130 |
Why?
| | Coronary Vessels | 6 | 2020 | 230 | 1.070 |
Why?
| | Female | 80 | 2023 | 59617 | 1.050 |
Why?
| | Myocardial Ischemia | 4 | 2020 | 236 | 1.010 |
Why?
| | Angina, Stable | 3 | 2022 | 17 | 1.000 |
Why?
| | Coated Materials, Biocompatible | 6 | 2020 | 54 | 0.950 |
Why?
| | Patient Readmission | 7 | 2022 | 606 | 0.940 |
Why?
| | Cardiology | 4 | 2022 | 259 | 0.940 |
Why?
| | Retrospective Studies | 43 | 2023 | 12548 | 0.910 |
Why?
| | Myocardial Reperfusion | 2 | 2013 | 49 | 0.890 |
Why?
| | Quality of Health Care | 2 | 2019 | 573 | 0.880 |
Why?
| | Stroke Volume | 3 | 2021 | 510 | 0.880 |
Why?
| | Ventricular Function, Left | 3 | 2021 | 469 | 0.850 |
Why?
| | Vascular Patency | 14 | 2020 | 97 | 0.850 |
Why?
| | Chickens | 1 | 2023 | 177 | 0.840 |
Why?
| | Heart Arrest | 3 | 2017 | 289 | 0.830 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 152 | 0.820 |
Why?
| | Psoriasis | 1 | 2023 | 74 | 0.820 |
Why?
| | Vascular Access Devices | 5 | 2020 | 24 | 0.800 |
Why?
| | Coronary Thrombosis | 4 | 2015 | 25 | 0.800 |
Why?
| | Quality Improvement | 2 | 2019 | 953 | 0.790 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2023 | 372 | 0.790 |
Why?
| | California | 18 | 2019 | 364 | 0.790 |
Why?
| | Aged, 80 and over | 21 | 2021 | 6357 | 0.770 |
Why?
| | Anemia | 2 | 2022 | 144 | 0.760 |
Why?
| | Coronary Occlusion | 2 | 2023 | 18 | 0.740 |
Why?
| | Heart Failure, Systolic | 1 | 2021 | 20 | 0.740 |
Why?
| | Hemorrhage | 5 | 2022 | 618 | 0.740 |
Why?
| | Hospitals, Community | 1 | 2020 | 45 | 0.700 |
Why?
| | Cardiac Surgical Procedures | 2 | 2022 | 413 | 0.700 |
Why?
| | Drug-Eluting Stents | 6 | 2017 | 62 | 0.700 |
Why?
| | Paclitaxel | 2 | 2019 | 190 | 0.690 |
Why?
| | Assisted Circulation | 1 | 2019 | 25 | 0.680 |
Why?
| | Cardiac Catheterization | 4 | 2023 | 535 | 0.680 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 40 | 0.670 |
Why?
| | Postoperative Hemorrhage | 1 | 2020 | 75 | 0.660 |
Why?
| | Practice Patterns, Physicians' | 6 | 2021 | 1178 | 0.660 |
Why?
| | Embolic Protection Devices | 1 | 2019 | 11 | 0.650 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2019 | 16 | 0.650 |
Why?
| | Saphenous Vein | 1 | 2019 | 31 | 0.650 |
Why?
| | Graft Occlusion, Vascular | 1 | 2019 | 35 | 0.650 |
Why?
| | Fibrinolytic Agents | 2 | 2018 | 233 | 0.630 |
Why?
| | Electrocardiography | 4 | 2015 | 562 | 0.630 |
Why?
| | Arterial Occlusive Diseases | 1 | 2018 | 73 | 0.600 |
Why?
| | Odds Ratio | 8 | 2021 | 957 | 0.590 |
Why?
| | Arm | 1 | 2018 | 104 | 0.590 |
Why?
| | Peripheral Vascular Diseases | 1 | 2018 | 98 | 0.590 |
Why?
| | Thromboembolism | 1 | 2018 | 93 | 0.590 |
Why?
| | Kaplan-Meier Estimate | 12 | 2020 | 814 | 0.580 |
Why?
| | Cerebrovascular Disorders | 1 | 2018 | 83 | 0.580 |
Why?
| | Aspirin | 2 | 2019 | 324 | 0.570 |
Why?
| | Heart Failure | 6 | 2023 | 1962 | 0.570 |
Why?
| | Limb Salvage | 7 | 2019 | 52 | 0.570 |
Why?
| | Renal Artery | 1 | 2017 | 26 | 0.560 |
Why?
| | Renal Artery Obstruction | 1 | 2017 | 29 | 0.550 |
Why?
| | Embolism | 1 | 2017 | 43 | 0.550 |
Why?
| | Hospitals | 4 | 2023 | 582 | 0.550 |
Why?
| | Propensity Score | 5 | 2021 | 224 | 0.540 |
Why?
| | Research Report | 1 | 2017 | 75 | 0.540 |
Why?
| | Catheterization | 3 | 2021 | 159 | 0.520 |
Why?
| | Databases, Factual | 10 | 2020 | 1132 | 0.510 |
Why?
| | Hospitalization | 3 | 2021 | 1755 | 0.500 |
Why?
| | Iliac Artery | 4 | 2019 | 44 | 0.500 |
Why?
| | Coronary Stenosis | 5 | 2020 | 39 | 0.500 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 201 | 0.470 |
Why?
| | Cohort Studies | 10 | 2023 | 4904 | 0.470 |
Why?
| | Disclosure | 1 | 2015 | 101 | 0.470 |
Why?
| | Atherosclerosis | 3 | 2019 | 342 | 0.460 |
Why?
| | Thrombectomy | 2 | 2014 | 52 | 0.460 |
Why?
| | Cell Separation | 1 | 2015 | 291 | 0.450 |
Why?
| | Depressive Disorder | 1 | 2017 | 333 | 0.450 |
Why?
| | Vascular Surgical Procedures | 1 | 2016 | 259 | 0.440 |
Why?
| | Survival Rate | 6 | 2021 | 1646 | 0.430 |
Why?
| | Disease Management | 1 | 2017 | 563 | 0.420 |
Why?
| | Attitude of Health Personnel | 1 | 2019 | 976 | 0.410 |
Why?
| | Logistic Models | 6 | 2017 | 1839 | 0.400 |
Why?
| | HIV | 1 | 2013 | 208 | 0.400 |
Why?
| | Predictive Value of Tests | 8 | 2020 | 1812 | 0.390 |
Why?
| | Intermittent Claudication | 3 | 2017 | 108 | 0.390 |
Why?
| | Incidence | 7 | 2021 | 2318 | 0.380 |
Why?
| | Hypothermia | 1 | 2011 | 39 | 0.370 |
Why?
| | Cause of Death | 3 | 2023 | 364 | 0.370 |
Why?
| | Contrast Media | 3 | 2023 | 369 | 0.350 |
Why?
| | Mentoring | 2 | 2023 | 101 | 0.350 |
Why?
| | Endothelial Cells | 1 | 2015 | 685 | 0.340 |
Why?
| | Proportional Hazards Models | 9 | 2023 | 1080 | 0.340 |
Why?
| | Mortality | 3 | 2020 | 287 | 0.340 |
Why?
| | Constriction, Pathologic | 9 | 2020 | 210 | 0.330 |
Why?
| | Peptide Fragments | 2 | 2015 | 668 | 0.320 |
Why?
| | Severity of Illness Index | 7 | 2022 | 2551 | 0.320 |
Why?
| | Chi-Square Distribution | 4 | 2018 | 498 | 0.320 |
Why?
| | Laser Therapy | 2 | 2019 | 99 | 0.310 |
Why?
| | Punctures | 2 | 2019 | 36 | 0.310 |
Why?
| | Angiography | 6 | 2020 | 177 | 0.310 |
Why?
| | Transcatheter Aortic Valve Replacement | 2 | 2021 | 152 | 0.300 |
Why?
| | Acute Kidney Injury | 4 | 2023 | 638 | 0.300 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2008 | 96 | 0.300 |
Why?
| | Carotid Stenosis | 2 | 2018 | 79 | 0.290 |
Why?
| | Myocardial Perfusion Imaging | 2 | 2019 | 36 | 0.280 |
Why?
| | HIV Infections | 3 | 2023 | 2470 | 0.280 |
Why?
| | Recurrence | 9 | 2019 | 941 | 0.280 |
Why?
| | Hypertension, Pulmonary | 3 | 2023 | 1736 | 0.270 |
Why?
| | Macrophages | 3 | 2008 | 1267 | 0.270 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2023 | 486 | 0.270 |
Why?
| | Emergency Medical Services | 1 | 2013 | 587 | 0.270 |
Why?
| | Patient Discharge | 3 | 2022 | 767 | 0.260 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1435 | 0.260 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2021 | 361 | 0.260 |
Why?
| | Acute Disease | 3 | 2017 | 915 | 0.260 |
Why?
| | Quality Indicators, Health Care | 2 | 2019 | 287 | 0.250 |
Why?
| | Purinergic P2Y Receptor Antagonists | 2 | 2023 | 62 | 0.250 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4420 | 0.250 |
Why?
| | Chest Pain | 3 | 2022 | 81 | 0.240 |
Why?
| | Comorbidity | 5 | 2020 | 1457 | 0.240 |
Why?
| | Pancreas | 2 | 2004 | 280 | 0.240 |
Why?
| | Cross-Sectional Studies | 6 | 2022 | 4411 | 0.230 |
Why?
| | Surgical Procedures, Operative | 2 | 2017 | 207 | 0.230 |
Why?
| | Stroke | 6 | 2022 | 1015 | 0.230 |
Why?
| | Prosthesis Failure | 2 | 2016 | 116 | 0.220 |
Why?
| | Prognosis | 6 | 2021 | 3335 | 0.220 |
Why?
| | Coronary Circulation | 2 | 2014 | 135 | 0.220 |
Why?
| | Fractional Flow Reserve, Myocardial | 2 | 2020 | 8 | 0.210 |
Why?
| | Healthcare Disparities | 2 | 2019 | 480 | 0.210 |
Why?
| | Biological Therapy | 1 | 2023 | 26 | 0.210 |
Why?
| | New York | 3 | 2017 | 107 | 0.210 |
Why?
| | Critical Illness | 8 | 2020 | 645 | 0.210 |
Why?
| | Chronic Disease | 5 | 2023 | 1591 | 0.200 |
Why?
| | Work Engagement | 1 | 2022 | 9 | 0.200 |
Why?
| | Leukocytes | 1 | 2003 | 277 | 0.200 |
Why?
| | Social Class | 1 | 2023 | 205 | 0.200 |
Why?
| | Technology Transfer | 1 | 2021 | 13 | 0.190 |
Why?
| | Anticoagulants | 2 | 2016 | 546 | 0.190 |
Why?
| | Cardiologists | 1 | 2021 | 40 | 0.180 |
Why?
| | Shock, Cardiogenic | 2 | 2021 | 53 | 0.180 |
Why?
| | Aftercare | 1 | 2022 | 186 | 0.180 |
Why?
| | Angina Pectoris | 1 | 2020 | 63 | 0.180 |
Why?
| | Exercise Test | 2 | 2022 | 545 | 0.180 |
Why?
| | Mandatory Reporting | 2 | 2017 | 45 | 0.180 |
Why?
| | Thrombocytopenia | 1 | 2022 | 178 | 0.170 |
Why?
| | Massachusetts | 2 | 2017 | 136 | 0.170 |
Why?
| | Delivery of Health Care | 2 | 2023 | 835 | 0.170 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 1081 | 0.170 |
Why?
| | Biomarkers | 4 | 2017 | 3419 | 0.170 |
Why?
| | Echocardiography, Stress | 1 | 2019 | 20 | 0.170 |
Why?
| | Health Facilities | 1 | 2019 | 72 | 0.160 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2019 | 47 | 0.160 |
Why?
| | Peer Review | 1 | 2019 | 43 | 0.160 |
Why?
| | Fluid Therapy | 1 | 2020 | 122 | 0.160 |
Why?
| | Thrombosis | 1 | 2022 | 301 | 0.160 |
Why?
| | Vascular Resistance | 1 | 2020 | 337 | 0.160 |
Why?
| | Perioperative Care | 1 | 2020 | 125 | 0.160 |
Why?
| | Intraoperative Period | 1 | 2019 | 51 | 0.160 |
Why?
| | Heart | 1 | 2022 | 610 | 0.160 |
Why?
| | Colorado | 8 | 2019 | 4089 | 0.160 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2098 | 0.160 |
Why?
| | Centralized Hospital Services | 1 | 2018 | 6 | 0.160 |
Why?
| | Perception | 1 | 2021 | 310 | 0.150 |
Why?
| | Secondary Prevention | 1 | 2019 | 222 | 0.150 |
Why?
| | Hemodynamics | 3 | 2023 | 1017 | 0.150 |
Why?
| | Angioplasty, Balloon, Laser-Assisted | 1 | 2017 | 1 | 0.150 |
Why?
| | Disease-Free Survival | 5 | 2017 | 617 | 0.150 |
Why?
| | Algorithms | 2 | 2017 | 1489 | 0.150 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2019 | 78 | 0.150 |
Why?
| | Transportation of Patients | 1 | 2018 | 52 | 0.150 |
Why?
| | Angioplasty | 1 | 2018 | 40 | 0.150 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2017 | 14 | 0.150 |
Why?
| | Cardiac Catheters | 1 | 2017 | 15 | 0.150 |
Why?
| | Pulmonary Artery | 1 | 2023 | 1028 | 0.150 |
Why?
| | Rosuvastatin Calcium | 1 | 2017 | 17 | 0.150 |
Why?
| | Computer Simulation | 1 | 2021 | 881 | 0.150 |
Why?
| | ADAMTS13 Protein | 1 | 2017 | 4 | 0.140 |
Why?
| | Macrophage Colony-Stimulating Factor | 2 | 2008 | 17 | 0.140 |
Why?
| | Cardiovascular Diseases | 2 | 2020 | 1729 | 0.140 |
Why?
| | Thrombotic Microangiopathies | 1 | 2017 | 12 | 0.140 |
Why?
| | Neck | 1 | 2017 | 84 | 0.140 |
Why?
| | Ankle Brachial Index | 1 | 2017 | 30 | 0.140 |
Why?
| | Risk | 2 | 2019 | 815 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2022 | 321 | 0.140 |
Why?
| | Suction | 2 | 2014 | 31 | 0.140 |
Why?
| | Policy Making | 1 | 2017 | 81 | 0.140 |
Why?
| | Flow Cytometry | 2 | 2015 | 1084 | 0.140 |
Why?
| | Adult | 6 | 2019 | 30658 | 0.140 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 245 | 0.130 |
Why?
| | Academic Medical Centers | 2 | 2016 | 412 | 0.130 |
Why?
| | Boston | 1 | 2016 | 75 | 0.130 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1203 | 0.130 |
Why?
| | Postoperative Complications | 3 | 2021 | 2150 | 0.130 |
Why?
| | Aortic Valve Stenosis | 1 | 2019 | 272 | 0.130 |
Why?
| | Pandemics | 2 | 2021 | 1322 | 0.130 |
Why?
| | Dyslipidemias | 1 | 2017 | 154 | 0.130 |
Why?
| | Aortic Valve | 1 | 2019 | 399 | 0.130 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1523 | 0.130 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2018 | 231 | 0.130 |
Why?
| | Cholesterol | 2 | 2008 | 368 | 0.120 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2007 | 193 | 0.120 |
Why?
| | Antithrombins | 1 | 2015 | 49 | 0.120 |
Why?
| | Prevalence | 2 | 2019 | 2255 | 0.120 |
Why?
| | Contraindications | 1 | 2014 | 86 | 0.120 |
Why?
| | Aortic Diseases | 1 | 2016 | 108 | 0.120 |
Why?
| | Prospective Studies | 3 | 2020 | 6232 | 0.120 |
Why?
| | Collateral Circulation | 1 | 2014 | 19 | 0.120 |
Why?
| | Models, Cardiovascular | 1 | 2015 | 179 | 0.120 |
Why?
| | Heparin | 1 | 2015 | 222 | 0.110 |
Why?
| | Diabetes Mellitus | 2 | 2018 | 906 | 0.110 |
Why?
| | Incidental Findings | 1 | 2013 | 76 | 0.110 |
Why?
| | Resuscitation | 1 | 2015 | 248 | 0.110 |
Why?
| | Primary Prevention | 1 | 2014 | 171 | 0.110 |
Why?
| | Electronic Health Records | 2 | 2017 | 799 | 0.110 |
Why?
| | Health Services Accessibility | 1 | 2018 | 765 | 0.100 |
Why?
| | Smoking Cessation | 1 | 2016 | 376 | 0.100 |
Why?
| | Coronary Disease | 1 | 2014 | 347 | 0.100 |
Why?
| | Trazodone | 1 | 2011 | 2 | 0.100 |
Why?
| | Antimanic Agents | 1 | 2011 | 15 | 0.100 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2023 | 71 | 0.100 |
Why?
| | Lithium | 1 | 2011 | 36 | 0.100 |
Why?
| | Triazines | 1 | 2011 | 36 | 0.100 |
Why?
| | Decision Support Techniques | 1 | 2014 | 351 | 0.090 |
Why?
| | American Heart Association | 2 | 2022 | 264 | 0.090 |
Why?
| | Prosthesis Design | 3 | 2017 | 285 | 0.090 |
Why?
| | Laboratories | 2 | 2022 | 95 | 0.090 |
Why?
| | Benzodiazepines | 1 | 2011 | 116 | 0.090 |
Why?
| | Depression | 1 | 2018 | 1136 | 0.090 |
Why?
| | Cell Differentiation | 2 | 2008 | 1700 | 0.090 |
Why?
| | Age Factors | 4 | 2019 | 2894 | 0.090 |
Why?
| | Anticonvulsants | 1 | 2011 | 178 | 0.080 |
Why?
| | Bipolar Disorder | 1 | 2011 | 208 | 0.080 |
Why?
| | Lipoproteins, LDL | 2 | 2007 | 129 | 0.080 |
Why?
| | MicroRNAs | 1 | 2015 | 603 | 0.080 |
Why?
| | Seizures | 1 | 2011 | 341 | 0.080 |
Why?
| | Pinocytosis | 1 | 2007 | 10 | 0.070 |
Why?
| | Sex Factors | 3 | 2019 | 1721 | 0.070 |
Why?
| | Area Under Curve | 1 | 2008 | 275 | 0.070 |
Why?
| | Monocytes | 2 | 2007 | 503 | 0.070 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 140 | 0.070 |
Why?
| | Ultrasonography, Doppler, Duplex | 2 | 2017 | 39 | 0.070 |
Why?
| | Reproducibility of Results | 3 | 2022 | 2799 | 0.070 |
Why?
| | Phenotype | 2 | 2021 | 2815 | 0.070 |
Why?
| | Drug Overdose | 1 | 2011 | 293 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 396 | 0.070 |
Why?
| | Inflammation | 3 | 2008 | 2485 | 0.070 |
Why?
| | ROC Curve | 1 | 2008 | 447 | 0.070 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2019 | 294 | 0.070 |
Why?
| | Exercise | 1 | 2016 | 1644 | 0.070 |
Why?
| | Shock | 2 | 2004 | 75 | 0.060 |
Why?
| | Animals | 3 | 2023 | 31868 | 0.060 |
Why?
| | Equipment Design | 2 | 2018 | 513 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 999 | 0.060 |
Why?
| | Lipid Metabolism | 1 | 2008 | 449 | 0.060 |
Why?
| | Length of Stay | 2 | 2019 | 951 | 0.060 |
Why?
| | Program Evaluation | 2 | 2019 | 825 | 0.060 |
Why?
| | Hypoglycemic Agents | 2 | 2023 | 1006 | 0.060 |
Why?
| | Survival Analysis | 2 | 2020 | 1211 | 0.060 |
Why?
| | Trypsin | 1 | 2004 | 67 | 0.060 |
Why?
| | Amylases | 1 | 2003 | 14 | 0.060 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2004 | 119 | 0.060 |
Why?
| | Chymotrypsin | 1 | 2003 | 17 | 0.060 |
Why?
| | Ezetimibe | 1 | 2023 | 24 | 0.060 |
Why?
| | Observer Variation | 2 | 2014 | 298 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2003 | 286 | 0.050 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2023 | 100 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 955 | 0.050 |
Why?
| | Pancreatitis | 1 | 2003 | 107 | 0.050 |
Why?
| | Rats, Wistar | 1 | 2003 | 369 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1398 | 0.050 |
Why?
| | Personnel Turnover | 1 | 2022 | 27 | 0.050 |
Why?
| | Cell Death | 1 | 2003 | 324 | 0.050 |
Why?
| | Reperfusion Injury | 1 | 2004 | 254 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2023 | 307 | 0.050 |
Why?
| | Disease Progression | 2 | 2019 | 2389 | 0.050 |
Why?
| | Neutrophils | 2 | 2004 | 1164 | 0.050 |
Why?
| | Organizational Culture | 1 | 2022 | 119 | 0.050 |
Why?
| | Troponin | 1 | 2021 | 44 | 0.050 |
Why?
| | Systole | 1 | 2021 | 171 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2007 | 1318 | 0.040 |
Why?
| | Consensus | 1 | 2023 | 534 | 0.040 |
Why?
| | Job Satisfaction | 1 | 2022 | 167 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2008 | 3896 | 0.040 |
Why?
| | Cytokines | 1 | 2008 | 1843 | 0.040 |
Why?
| | Sodium Bicarbonate | 1 | 2020 | 40 | 0.040 |
Why?
| | Free Radical Scavengers | 1 | 2020 | 78 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2021 | 213 | 0.040 |
Why?
| | Sodium | 1 | 2020 | 183 | 0.040 |
Why?
| | Hypertension | 2 | 2018 | 1058 | 0.040 |
Why?
| | Hospitals, High-Volume | 1 | 2019 | 39 | 0.040 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2019 | 76 | 0.040 |
Why?
| | Cost Savings | 1 | 2019 | 74 | 0.040 |
Why?
| | Acetylcysteine | 1 | 2020 | 142 | 0.040 |
Why?
| | Endocrinologists | 1 | 2018 | 12 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 130 | 0.040 |
Why?
| | Retreatment | 1 | 2018 | 67 | 0.040 |
Why?
| | Drug Utilization | 1 | 2019 | 167 | 0.040 |
Why?
| | Rats | 2 | 2004 | 4973 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 180 | 0.040 |
Why?
| | Transcription Factors | 1 | 2006 | 1531 | 0.040 |
Why?
| | Singapore | 1 | 2017 | 15 | 0.040 |
Why?
| | Republic of Korea | 1 | 2017 | 27 | 0.040 |
Why?
| | Angina, Unstable | 1 | 2017 | 72 | 0.040 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2017 | 8 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1127 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2020 | 604 | 0.030 |
Why?
| | New Jersey | 1 | 2016 | 8 | 0.030 |
Why?
| | Ultrasonography, Interventional | 1 | 2017 | 123 | 0.030 |
Why?
| | Tomography, Optical Coherence | 1 | 2017 | 130 | 0.030 |
Why?
| | Michigan | 1 | 2016 | 96 | 0.030 |
Why?
| | Aortography | 1 | 2016 | 50 | 0.030 |
Why?
| | Postoperative Care | 1 | 2017 | 222 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 900 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2019 | 492 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2016 | 94 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2017 | 239 | 0.030 |
Why?
| | Hirudins | 1 | 2015 | 46 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 776 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2022 | 1901 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2017 | 276 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 937 | 0.030 |
Why?
| | Blood Coagulation | 1 | 2016 | 221 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2108 | 0.030 |
Why?
| | Protective Factors | 1 | 2014 | 87 | 0.030 |
Why?
| | Lipids | 1 | 2017 | 586 | 0.030 |
Why?
| | Health Policy | 1 | 2016 | 334 | 0.030 |
Why?
| | Emergencies | 1 | 2013 | 147 | 0.030 |
Why?
| | Blood Flow Velocity | 1 | 2014 | 390 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2389 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1237 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 544 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 489 | 0.020 |
Why?
| | Health Care Costs | 1 | 2014 | 381 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 4631 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1636 | 0.020 |
Why?
| | Medicare | 1 | 2014 | 666 | 0.020 |
Why?
| | Clofibrate | 1 | 2007 | 4 | 0.020 |
Why?
| | Orphan Nuclear Receptors | 1 | 2007 | 14 | 0.020 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2007 | 15 | 0.020 |
Why?
| | Hydrocarbons, Fluorinated | 1 | 2007 | 9 | 0.020 |
Why?
| | Liver X Receptors | 1 | 2007 | 30 | 0.020 |
Why?
| | beta-Cyclodextrins | 1 | 2007 | 28 | 0.020 |
Why?
| | Physicians | 1 | 2013 | 772 | 0.020 |
Why?
| | Telemedicine | 1 | 2013 | 665 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 599 | 0.020 |
Why?
| | Mesenteric Arteries | 1 | 2004 | 16 | 0.010 |
Why?
| | Jejunum | 1 | 2004 | 24 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2006 | 297 | 0.010 |
Why?
| | Gelatin | 1 | 2004 | 36 | 0.010 |
Why?
| | Sulfonamides | 1 | 2007 | 446 | 0.010 |
Why?
| | Peroxidase | 1 | 2004 | 157 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2004 | 398 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 791 | 0.010 |
Why?
| | Blotting, Western | 1 | 2004 | 1149 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2212 | 0.010 |
Why?
|
|
Waldo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|